Company / SG&A Expense
Spyre Therapeutics, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$47.9M
FY2025
5-year range
$21.8M / $47.9M
FY2021-FY2025
Trend
+4.7%
vs FY2024
Sector context
#164 of 213
Health Care
What the data says
Spyre Therapeutics, Inc.'s sg&a expense of $48M is lower than 77% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 3 consecutive years, from $22M in FY2022 to $48M in FY2025.
Based on SEC 10-K filings.
$48M in FY2025 with a 5-year CAGR of +30.6%.
Increased from $40M to $48M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +29.9%
- 5-Year CAGR
- +30.6%
- 10-Year CAGR
- -
Sector benchmark
Top 23% in Health CareTop 23% of 213This company $47.9M Sector average $722.3M
▼
-93.4% below sector average
Key checks
Key Insights
- Spyre Therapeutics, Inc.'s sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +30.6%, indicating consistent growth.
- In FY2025, sg&a expense increased 4.7% year-over-year.
- Ranks #164 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $47.9M | +4.7% |
| FY2024 | $45.8M | +14.6% |
| FY2023 | $39.9M | +82.9% |
| FY2022 | $21.8M | -20.0% |
| FY2021 | $27.3M | +116.3% |
| FY2020 | $12.6M | +25.5% |
| FY2019 | $10.1M | +20.0% |
| FY2018 | $8.4M | -16.6% |
| FY2017 | $10.1M | +20.0% |
| FY2016 | $8.4M | +41.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026